n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial

Abdominal aortic aneurysm (AAA) is an important cause of death in older adults, which has no current drug therapy. Inflammation and abnormal redox status are believed to be key pathogenic mechanisms for AAA. In light of evidence correlating inflammation with aberrant fatty acid profiles, this study compared erythrocyte fatty acid content in 43 AAA patients (diameter 3.0-4.5 cm) and 52 healthy controls. In addition, the effect of omega-3 PUFA (n-3 PUFA) supplementation on erythrocyte fatty acid content was examined in a cohort of 30 AAA patients as part of a 12 week randomized placebo-controlled clinical trial. Blood analyses identified associations between AAA and decreased linoleic acid (LA), and AAA and increased 6-desaturase activity and biosynthesis of arachidonic acid (AA) from LA. Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day) decreased red blood cell distribution width (14.8 +/- 0.4% to 13.8 +/- 0.2%; P = 0.003) and levels of pro-inflammatory n-6 PUFAs (AA, 12.46 +/- 0.23% to 10.14 +/- 0.3%, P < 0.001; adrenic acid, 2.12 +/- 0.13% to 1.23 +/- 0.09%; P < 0.001). In addition, -4 desaturase activity increased (DHA/docosapentaenoic acid ratio, 1.85 +/- 0.14 to 3.93 +/- 0.17; P < 0.001) and elongase 2/5 activity decreased (adrenic acid/AA ratio, 0.17 +/- 0.01 to 0.12 +/- 0.01; P < 0.01) following supplementation. The findings suggest that n-3 PUFAs improve fatty acid profiles and ameliorate factors associated with inflammation in AAA patients.